Specialty pharma Tesorx Pharma LLC looked to muscle in on the testosterone market by closing a $10 million series B-1 funding from existing and new private investors to prepare for phase III trials of lead compound TSX-002, a first-in-class oral formulation of unmodified testosterone, and to build out its commercial manufacturing facilities to scale up for the pivotal trial and commercial production.